{"page":{"totalFilteredElements":14},"studies":[{"active":true,"description":"Randomized, placebo controlled Phase III Study of Induction and Consolidation chemotherapy with Venetoclax in adult patients with newly diagnosed acute myeloid Leukemia or Myelodyspalstic syndrome with ecxess Blasts-2","eudractNumber":"2023-507518-28-00","id":11260,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":"NCT04628026","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-08-05T09:00:15+02:00","shortTitle":"AMLSG 31-19","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>Registerstudie zum biologischen Erkrankungsprofil und klinischen Verlauf bei der akuten myeloischen Leuk&#228;mie und verwandten Vorl&#228;ufer-Neoplasien und der akuten Leuk&#228;mie unklarer Linienzugeh&#246;rigkeit: Das AMLSG Biology and Outcome (BIO)-Projekt</div>","eudractNumber":null,"id":953,"indications":[{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":"NCT01252485","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2013-08-01T09:31:52+02:00","shortTitle":"AMLSG BIO","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Multicenter, Open-label, Phase 1 Study of Allo-RevCAR01-T-CD123&#160;Consisting of Genetically Modified T cells Carrying Reverse Chimeric&#160;Antigen Receptors (Allo-RevCAR01-T) in Combination With CD123&#160;Target Module (R-TM123) for the Treatment of Patients With Selected&#160;Hematologic Malignancies Positive for CD123","eudractNumber":"2022-501797-19","id":8333,"indications":[{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[{"name":"CD (Cluster of Differentiation)","id":"mt_211"},{"name":"CD123 ","id":"mt_79"}],"nctNumber":"NCT05949125","phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2024-02-20T12:24:52+01:00","shortTitle":"AVC-201-01","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"<div>A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2ARearrangements or NPM1Mutations who are Ineligible for Intensive Chemotherapy</div>","eudractNumber":"2024-520154-38","id":10760,"indications":[{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-01-20T10:27:50+01:00","shortTitle":"CAMELOT - 2 75276617 AML3001","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<p class=\"MsoNormal\">Deutsches Register f&#252;r Stammzelltransplantationen / EBMT\nRegistry on stem cell transplantation (DRST)</p>","eudractNumber":null,"id":6852,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"leu","name":"Leukämien"},{"id":"leu1","name":"Akute lymphatische Leukämie und Burkitt-Lymphom (ALL)"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"},{"id":"leu3","name":"Chronische myeloische Leukämie (CML)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2005-01-03T13:23:27+01:00","shortTitle":"Deutsches Register für Stammzelltransplantationen - MZoL-FL Register / EBMT Registry on stem cell transplantation","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Nicht-Interventionelle Studie (NIS) zum klinischen Einsatz von Octagam 5%, Octagam 10% oder panzyga<br />","eudractNumber":null,"id":6546,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2020-04-01T11:55:14+02:00","shortTitle":"GAM-36","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Nicht-Interventionelle Studie (NIS) zum klinischen Einsatz von Octagam 5%, Octagam 10% oder panzyga<br />","eudractNumber":null,"id":11341,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-01-28T09:00:35+01:00","shortTitle":"GAM-36","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Deutsches MPN-Register und Biomaterialbank f&#252;r BCR-ABL1-negative myeloische Neoplasien<br />","eudractNumber":null,"id":4799,"indications":[{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"},{"id":"leu3","name":"Chronische myeloische Leukämie (CML)"},{"id":"leu4","name":"Weitere hämatologische Neoplasien"}],"mutations":[{"name":"ABL","id":"mt_203"},{"name":"bcr-abl","id":"mt_57"}],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2018-12-19T10:14:45+01:00","shortTitle":"GSG-MPN-Register","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"AML-Register und Biomaterialdatenbank der Studienallianz Leuk&#228;mie (SAL) und der AML Cooperative Group (AML-CG)<br />","eudractNumber":null,"id":370,"indications":[{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2011-09-23T09:28:47+02:00","shortTitle":"Klinisches AML-Register (SAL, AML-CG)","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"AML-Register und Biomaterialdatenbank der Studienallianz Leuk&#228;mie (SAL) und der AML Cooperative Group (AML-CG)","eudractNumber":null,"id":5759,"indications":[{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2019-04-29T12:55:09+02:00","shortTitle":"Klinisches AML-Register (SAL, AML-CG)","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]}]}